Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Mortality among tuberculosis patients with acquired resistance to second-line antituberculosis drugs--United States, 1993-2008.

Ershova JV, Kurbatova EV, Moonan PK, Cegielski JP.

Clin Infect Dis. 2014 Aug 15;59(4):465-72. doi: 10.1093/cid/ciu372. Epub 2014 May 20.

2.

Acquired resistance to second-line drugs among persons with tuberculosis in the United States.

Ershova JV, Kurbatova EV, Moonan PK, Cegielski JP.

Clin Infect Dis. 2012 Dec;55(12):1600-7. doi: 10.1093/cid/cis748. Epub 2012 Aug 31.

3.

Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai.

Chen Y, Yuan Z, Shen X, Wu J, Wu Z, Xu B.

Biomed Res Int. 2016;2016:2628913. doi: 10.1155/2016/2628913. Epub 2016 Aug 29.

4.

Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

Cegielski JP, Dalton T, Yagui M, Wattanaamornkiet W, Volchenkov GV, Via LE, Van Der Walt M, Tupasi T, Smith SE, Odendaal R, Leimane V, Kvasnovsky C, Kuznetsova T, Kurbatova E, Kummik T, Kuksa L, Kliiman K, Kiryanova EV, Kim H, Kim CK, Kazennyy BY, Jou R, Huang WL, Ershova J, Erokhin VV, Diem L, Contreras C, Cho SN, Chernousova LN, Chen MP, Caoili JC, Bayona J, Akksilp S; Global Preserving Effective TB Treatment Study (PETTS) Investigators.

Clin Infect Dis. 2014 Oct 15;59(8):1049-63. doi: 10.1093/cid/ciu572. Epub 2014 Jul 23.

5.

Association between Mycobacterium tuberculosis complex phylogenetic lineage and acquired drug resistance.

Yuen CM, Kurbatova EV, Click ES, Cavanaugh JS, Cegielski JP.

PLoS One. 2013 Dec 23;8(12):e83006. doi: 10.1371/journal.pone.0083006. eCollection 2013.

6.

Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.

Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Ershova J, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Vasilyeva IA, Dalton T, Cegielski JP.

PLoS Med. 2015 Dec 29;12(12):e1001932. doi: 10.1371/journal.pmed.1001932. eCollection 2015 Dec.

7.

Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance.

Cegielski JP, Kurbatova E, van der Walt M, Brand J, Ershova J, Tupasi T, Caoili JC, Dalton T, Contreras C, Yagui M, Bayona J, Kvasnovsky C, Leimane V, Kuksa L, Chen MP, Via LE, Hwang SH, Wolfgang M, Volchenkov GV, Somova T, Smith SE, Akksilp S, Wattanaamornkiet W, Kim HJ, Kim CK, Kazennyy BY, Khorosheva T, Kliiman K, Viiklepp P, Jou R, Huang AS, Vasilyeva IA, Demikhova OV; Global PETTS Investigators, Lancaster J, Odendaal R, Diem L, Perez TC, Gler T, Tan K, Bonilla C, Jave O, Asencios L, Yale G, Suarez C, Walker AT, Norvaisha I, Skenders G, Sture I, Riekstina V, Cirule A, Sigman E, Cho SN, Cai Y, Eum S, Lee J, Park S, Jeon D, Shamputa IC, Metchock B, Kuznetsova T, Akksilp R, Sitti W, Inyapong J, Kiryanova EV, Degtyareva I, Nemtsova ES, Levina K, Danilovits M, Kummik T, Lei YC, Huang WL, Erokhin VV, Chernousova LN, Andreevskaya SN, Larionova EE, Smirnova TG.

Clin Infect Dis. 2016 Feb 15;62(4):418-430. doi: 10.1093/cid/civ910. Epub 2015 Oct 27.

8.

Impact of second-line drug resistance on tuberculosis treatment outcomes in the United States: MDR-TB is bad enough.

Althomsons SP, Cegielski JP.

Int J Tuberc Lung Dis. 2012 Oct;16(10):1331-4. doi: 10.5588/ijtld.11.0812. Epub 2012 Aug 3.

PMID:
22863311
9.

Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests.

Zetola NM, Modongo C, Moonan PK, Ncube R, Matlhagela K, Sepako E, Collman RG, Bisson GP.

J Infect Dis. 2014 Jun 1;209(11):1754-63. doi: 10.1093/infdis/jiu040. Epub 2014 Jan 16.

10.

Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009.

Kurbatova EV, Cavanaugh JS, Dalton T, Click ES, Cegielski JP.

Clin Infect Dis. 2013 Oct;57(8):1081-93. doi: 10.1093/cid/cit452. Epub 2013 Jul 9.

11.

The T2 Mycobacterium tuberculosis genotype, predominant in Kampala, Uganda, shows negative correlation with antituberculosis drug resistance.

Lukoye D, Katabazi FA, Musisi K, Kateete DP, Asiimwe BB, Okee M, Joloba ML, Cobelens FG.

Antimicrob Agents Chemother. 2014 Jul;58(7):3853-9. doi: 10.1128/AAC.02338-13. Epub 2014 Apr 28.

12.

Antituberculosis drug resistance acquired during treatment: an analysis of cases reported in California, 1994-2006.

Porco TC, Oh P, Flood JM.

Clin Infect Dis. 2013 Mar;56(6):761-9. doi: 10.1093/cid/cis989. Epub 2012 Dec 7.

13.

Fluoroquinolone resistance in non-multidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates.

Ho J, Jelfs P, Sintchenko V.

Int J Infect Dis. 2014 Sep;26:149-53. doi: 10.1016/j.ijid.2014.03.1388. Epub 2014 Jul 30.

14.

Influence of antituberculosis drug resistance and Mycobacterium tuberculosis lineage on outcome in HIV-associated tuberculous meningitis.

Tho DQ, Török ME, Yen NT, Bang ND, Lan NT, Kiet VS, van Vinh Chau N, Dung NH, Day J, Farrar J, Wolbers M, Caws M.

Antimicrob Agents Chemother. 2012 Jun;56(6):3074-9. doi: 10.1128/AAC.00319-12. Epub 2012 Apr 2.

15.

An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993.

Chum HJ, O'Brien RJ, Chonde TM, Graf P, Rieder HL.

AIDS. 1996 Mar;10(3):299-309.

PMID:
8882670
16.

Acquired Drug Resistance in Mycobacterium tuberculosis and Poor Outcomes among Patients with Multidrug-Resistant Tuberculosis.

Kempker RR, Kipiani M, Mirtskhulava V, Tukvadze N, Magee MJ, Blumberg HM.

Emerg Infect Dis. 2015 Jun;21(6):992-1001. doi: 10.3201/eid2106.141873.

17.

Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005-2010.

Smith SE, Ershova J, Vlasova N, Nikishova E, Tarasova I, Eliseev P, Maryandyshev AO, Shemyakin IG, Kurbatova E, Cegielski JP.

Emerg Infect Dis. 2015 Jun;21(6):1002-11. doi: 10.3201/eid2106.141907.

18.

Resistance to first-line antituberculosis drugs in Spain, 2010-2011. RETUBES Study.

Blanquer R, Rodrigo T, Casals M, Ruiz Manzano J, García-García JM, Calpe JL, Valencia E, Pascual T, Mir I, Jiménez MÁ, Cañas F, Vidal R, Penas A, Caylà JA; Working Group of the Integrated Programme for Research in Tuberculosis in Spain.

Arch Bronconeumol. 2015 Jan;51(1):24-30. doi: 10.1016/j.arbres.2014.06.001. Epub 2014 Jul 11. English, Spanish.

19.

Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.

Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ.

Clin Infect Dis. 2007 Nov 15;45(10):1290-5. Epub 2007 Oct 15.

PMID:
17968823
20.

[Tuberculosis Laboratory Surveillance Network (TuLSA) study group. The first step for national tuberculosis laboratory surveillance: Ankara, 2011].

Sezen F, Albayrak N, Özkara Ş, Karagöz A, Alp A, Duyar Ağca F, İnan Süer A, Müderris T, Ceyhan İ, Durmaz R, Ertek M; Tüberküloz Laboratuvar Sürveyans Ağı Tulsa Çalışma Grubu, Tulsa.

Mikrobiyol Bul. 2015 Apr;49(2):143-55. Turkish.

Supplemental Content

Support Center